Kite Pharma is the Global University Venturing 2013 Investment of the Year.

Of all the different types of university research to be commercialised, biotechnology is perhaps the most difficult. There are multiple pitfalls, including high failure rates, drugs being blocked by regulators and management clashes that can cause a company to stagnate Any of these may scupper biotech as it is translated from labs to reality. But the most prominent problem is funding.

The ideal amount needed to bring a new drug to market stands at around $1bn.

The funding biotech attracts…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?